

1

2

3 An increase in willingness to vaccinate against COVID-19 in the US between October 2020

4 and February 2021: longitudinal evidence from the Understanding America Study

5

6 Michael Daly*¹ PhD, Andrew Jones² PhD, Eric Robinson^{2,3} PhD

7 ¹Department of Psychology, Maynooth University, Co. Kildare, Ireland

8 ²Department of Psychology, University of Liverpool, Liverpool, United Kingdom

9 ³Institute of Population Health Sciences, University of Liverpool, Liverpool, United

10 Kingdom

11

12 * Corresponding author: Michael Daly

13 Address correspondence to:

14 Michael Daly Ph.D.

15 Department of Psychology

16 1.1.7 Education House

17 Maynooth University

18 Maynooth

19 Ireland

20 Tel: (01) 474 7742

21 Email: Michael.A.Daly@mu.ie

22

23 **Word count:** 1,997/2,000

24 **Table/figure count:** 4

25 **Abstract**

26 *Background:* Recent evidence suggests that willingness to vaccinate against COVID-19 has
27 been declining throughout the pandemic and is low among ethnic minority groups.

28 *Methods:* Observational study using a nationally representative longitudinal sample (N
29 =7,840) from the Understanding America Study (UAS). Changes in the percentage of
30 respondents willing to vaccinate, undecided, or intending to refuse a COVID-19 vaccine were
31 examined over 20 survey waves from April 1 2020 to February 15 2021.

32 *Results:* After a sharp decline in willingness to vaccinate against COVID-19 between April
33 and October 2020 (from 74.0% to 52.7%), willingness to vaccinate increased by 8.1% (p
34 $<.001$) to 60.8% between October 2020 and February 2021. A significant increase in
35 willingness to vaccinate was observed across all demographic groups examined and Black
36 (15.6% increase) and Hispanic participants (12.1% increase) showed particularly large
37 changes.

38 *Conclusions:* Willingness to vaccinate against COVID-19 increased in the US from October
39 2020 to February 2021.

40 Funding statement: N/A

41

42 Key words: COVID-19, coronavirus, vaccination intentions, vaccine acceptance, vaccine
43 hesitancy

44

45

46

47

48 **1. Introduction**

49 As of February 28, 2021, the COVID-19 pandemic had led to over 2.6 million deaths
50 worldwide including over half a million deaths in the United States.¹ Since the beginning of
51 the pandemic on March 11, 2020, governments across the globe have enacted stringent
52 lockdown and distancing restrictions to curb the spread of the virus. As a result, the
53 pandemic has been linked to adverse societal outcomes including reduced national economic
54 output, declines in population mental health, and disruption to the provision of healthcare.^{2,3}
55 In this context, the rapid development of effective vaccines against COVID-19 offers a path
56 towards population immunity and a return to normal life.

57 Simulation studies suggest three quarters of the population may need to be vaccinated
58 to achieve herd immunity.⁴ However, recent large-scale reviews indicate that willingness to
59 vaccinate has been declining throughout the pandemic and may be insufficient to ensure
60 widespread vaccination.^{5,6} For instance, in the U.S. approximately half of adults indicated
61 they were willing to be vaccinated against COVID-19 in October 2020, down from over
62 70% in April, 2020.⁷

63 By mid-November 2020, results of the Pfizer-Biontech COVID-19 vaccine Phase 3
64 clinical trial were announced suggesting the vaccine was well tolerated and 95% effective
65 against the virus.⁸ The Pfizer-Biontech vaccine was subsequently approved by the U.S. FDA
66 for emergency use. This was followed by approval of two additional COVID-19 vaccines by
67 companies Moderna and Johnson & Johnson in December 2020 and February 2021
68 respectively.^{9,10} As of February 28, 2021, nations around the globe were accelerating their
69 vaccination programmes led by Israel where 54.5% of the population have received at least
70 one dose of a COVID-19 vaccine.¹¹

71 The widely publicized emergence of safe and effective vaccines against COVID-19
72 and the high-profile early successes of mass rollout programmes may have prompted an
73 increase in willingness to vaccinate. To evaluate this possibility, this research examined the
74 percentage of the U.S. population willing to vaccinate against COVID-19 across 20 waves of
75 the Understanding America Study (UAS), a nationally representative longitudinal study of
76 U.S. adults tracked continuously throughout the pandemic. Given concerns about high levels
77 of vaccine hesitancy among ethnic minority groups in the U.S. and elsewhere^{5,12,13} this study
78 also aimed to ascertain whether willingness to vaccinate has increased among Black and
79 Hispanic groups in recent months.

80 **2. Methods**

81 82 *2.1. Study design and participants*

83 Participants were drawn from the Understanding America Study, a probability-based
84 nationally representative internet-panel of U.S. adults aged 18 and over. The sample was
85 recruited via address-based sampling from the US postal addresses and participants without
86 internet access were provided with internet-connected tablet computers. Details of the UAS
87 survey administration and sampling methodology can found elsewhere.^{14,15}

88 In this study, 8547 eligible UAS participants were invited to take part in biweekly
89 surveys throughout the COVID-19 pandemic. In total, 7,840 participants provided 120,903
90 survey responses (15.4 surveys on average) across 20 waves of data collection conducted
91 between April 1 2020 and February 15 2021. Participants were assigned a specific day over
92 the course of each two-week survey period to complete the survey providing a continuous
93 account of willingness to vaccinate over this period. The number of participants included in
94 each survey wave and the dates of data collection can be seen in Table S1. The UAS was

95 approved by the University of Southern California human subjects committee internal review
96 board (IRB) and informed consent was obtained from all subjects.

97

98 2.2. *Measures*

99 In each wave of the survey participants were asked how likely they were to get vaccinated
100 against the coronavirus once a vaccine is available. Responses were categorized as either: (1)
101 undecided (responses of ‘unsure’), (2) unwilling to vaccinate (responses of somewhat or very
102 *unlikely* to vaccinate), or (3) willing to vaccinate (responses of somewhat or very *likely* to
103 vaccinate). From December 23 2020 participants were asked if they had received a COVID-
104 19 vaccine. Those who indicated they had received at least one dose of a COVID-19 vaccine
105 were included in the willing to vaccinate group.

106 Trends in willingness to vaccinate were examined across a set of demographic
107 subgroups based on participant age (18-39, 40-59, ≥ 60 years), sex (male, female),
108 race/ethnicity (White, Hispanic, Black, Other race/ethnicity), college degree (vs. none),
109 household income ($\leq \$50,000$, $\geq \$50,000$ per annum), and chronic health conditions (present vs
110 not present). To assess the presence of chronic health conditions participants indicated
111 whether they had been diagnosed with the following conditions: diabetes, cancer, heart
112 disease, kidney disease, asthma, chronic lung disease, an autoimmune disease.

113 2.3. *Statistical analysis*

114 National trends in the public’s willingness to vaccinate against COVID-19 were examined
115 across 20 waves of the UAS conducted between April 1 2020 and February 15 2021.
116 Multinomial logistic regression analysis with cluster robust standard errors were first
117 conducted. The Stata margins postestimation command was then used to estimate changes in
118 the predicted probabilities that participants were willing to vaccinate, undecided, or unwilling

119 to vaccinate at each time-point. Predicted probabilities were multiplied by 100 to represent
120 percentage point changes.

121 Our initial analyses confirmed that willingness to vaccinate declined from April to
122 October 2020 and increased after this point (see Figure 1). We therefore focused our in-depth
123 analysis of trends in willingness to vaccinate by demographic groups on changes from April
124 1-14 to the September 30-October 13 wave (hereafter October 2020) and between this point
125 and the January 20-February 15 2021 survey wave (hereafter February 2021). All analyses
126 were adjusted for demographic characteristics and incorporated the UAS sampling weights to
127 adjust for unequal probabilities of selection into the survey and align each survey wave with
128 the distribution of demographic characteristics of the US population.¹⁶

129 **3. Results**

130 *3.1. Sample characteristics*

131 Sample characteristics are displayed in Table 1. The participants were aged 48.8 (SD =16.6)
132 years on average, 51.5% were female and 66% were White, 16.2% Hispanic, 11.9% Black,
133 and 6% Other race/ethnicity and 33.9% reported being diagnosed with a chronic health
134 condition. On average across all time-points examined 59.5% of the sample indicated they
135 were willing to receive the COVID-19 vaccine when available, 12.4% of participants
136 indicated they were undecided, and 28.1% indicated they were unwilling accept the vaccine.

137 *3.2. National trends in willingness to vaccinate*

138 Trends in vaccination intentions between April 2020 and February 2021 are shown in Figure
139 1. There was a large drop in the percentage of participants willing to accept the vaccine from
140 73.8% at the beginning of April to 52.8% October 2020 that was observed in the overall
141 sample and across the demographic subgroups examined (see Table 2). At this point

142 willingness to vaccinate was lowest among Black participants (47.1%). From October 2020
143 willingness to vaccinate increased and 60.9% of adults were willing be vaccinated by
144 February 2021. This group included 10.5% of participants who reported having received at
145 least one dose of a COVID-19 vaccine by the February 2021 survey wave of the UAS.

146 In February 2021 29% of participants indicated they were unwilling to accept the
147 COVID-19 vaccine and this figure was particularly high among young adults, Black
148 participants, those without chronic conditions and lower income and education groups (see
149 Table 2).

150 *3.3. Regression analyses of changes in willingness to vaccinate between April 2020 and* 151 *February 2021*

152 Marginal effects computed from a multinomial logistic regression confirmed that the
153 percentage of participants willing to accept the vaccine declined significantly by 21.3% (95%
154 CI[19.4, 23.3], $p < .001$) from 74% to 52.7% between April and October 2020. This significant
155 decline was observed across demographic subgroups (see Table 3) and was explained by an
156 increase in the percentage of participants reporting they are undecided (4.7% increase, 95%
157 CI[3.1, 6.3], $p < .001$) or would refuse the COVID-19 vaccine (16.6% increase, 95% CI[14.8,
158 18.4], $p < .001$).

159 Intentions to vaccinate increased significantly by 8.1% (95% CI[6.3, 9.9], $p < .001$)
160 from 52.7% to 60.8% between October 2020 and February 2021 (see Table 3). This was
161 explained by a 4.9% (95% CI[3.5, 6.2], $p < .001$) decrease in the percentage of participants
162 indicating they were undecided about accepting the COVID-19 vaccine and a 3.2% (95%
163 CI[1.5, 5.0], $p < .001$) decline in the proportion of the population indicating they would refuse
164 the vaccine from October 2020 to February 2021 (Table 3).

165 Our regression analyses showed statistically significant increases in intentions to
166 vaccinate between October 2020 and February 2021 for all demographic groups examined
167 (Table 3). Over this period the largest increases in willingness to vaccinate were found
168 among Black (15.6% increase, 95% CI[9.6, 21.7], $p < .001$) and Hispanic participants (12.1%
169 increase, 95% CI[6.2, 17.9], $p < .001$). Those aged 40-59 years (10.5% increase, 95% CI[7.5,
170 13.4], $p < .001$), those with chronic health conditions (10.0% increase, 95% CI[7.0, 13.0],
171 $p < .001$), and females (9.7% increase, 95% CI[7.2, 12.1], $p < .001$) also showed relatively large
172 increases in willingness to vaccinate, as shown in Table 3.

173 **4. Discussion**

174 This is the first nationally representative study to show a longitudinal increase in willingness
175 to vaccinate since the emergence of evidence for the safety and efficacy of COVID-19
176 vaccines. After a rapid decline in intentions to vaccinate early in the pandemic,⁵⁻⁷ willingness
177 to vaccinate increased by over eight percentage points from 52.7% to 60.8% among U.S.
178 adults between October 2020 and February 2021. This was driven by a decline in the
179 percentage of participants reporting being undecided about vaccination and a decrease in the
180 percentage reporting they are unwilling to vaccinate. This trend is congruent with the findings
181 of a recent U.S. study that used repeated cross-sectional surveys to show a decline in
182 intentions to refuse the COVID-19 vaccine among priority groups between September and
183 December 2020.¹⁷

184 A significant increase in willingness to vaccinate was observed across all
185 demographic groups and was most pronounced among Black (15.6%) and Hispanic (12.1%)
186 participants. This increase is important because COVID-19 vaccine acceptance has been
187 particularly low among Black and Hispanic groups who are known to experience a
188 disproportionate burden of severe illness and death due to COVID-19.^{5,12,18} As such,

189 achieving a high levels of vaccine uptake among ethnic minority groups is crucial to reduce
190 racial inequalities in disease outcomes due to COVID-19. However, despite the gains seen in
191 recent months vaccine acceptance remained under 50% in Black participants in February
192 2021 and just above 60% in the overall sample. Furthermore, approximately one in three
193 Black participants explicitly reported they will not be vaccinated (vaccine refusal) and this
194 figure was similarly high among other population sub-groups (e.g. young adults, lower
195 income and education groups). For this reason, public health messaging needs to continue to
196 communicate the safety, efficacy and necessity of COVID-19 vaccines and to build trust in
197 vaccines, particularly among Black populations.^{12,19}

198 Understanding the drivers of changes in vaccination acceptance will now be critical in
199 shedding light on beliefs and concerns that could be targeted to promote vaccination uptake
200 and reduce loss of life due to the virus.¹⁸ Recent evidence suggests that there has been a
201 decline in concern about the speed at which COVID-19 vaccines have been developed
202 suggesting that the U.S. population has been at least partly assured that the science
203 underpinning the vaccines and the vaccine approval process has not been rushed.^{17,19}
204 However, public concerns about the safety and long-term health effects of the vaccine
205 remain. For this reason, further effort needs to be invested in conveying accurate safety
206 information through trusted sources (e.g. community groups, faith leaders, GPs) and tackling
207 vaccine misinformation.^{11,19-20}

208 The current study adds to the existing literature by examining national trends in
209 willingness to vaccinate in a large-scale nationally representative sample of adults tracked
210 continuously throughout the pandemic. However, the UAS is limited in that the survey is
211 administered to community dwelling adults in English and Spanish only and is accessible
212 only to those willing to engage with online surveys. This study is also limited in its reliance
213 on measures of intentions to vaccinate and reported vaccination behavior.

214 In conclusion, this longitudinal nationally representative study found that willingness
215 to vaccinate against COVID-19 has increased in the US from October 2020 to February 2021
216 and this increase has been largest in Black and Hispanic populations. However, almost 30%
217 of the US population still intend not to be vaccinated and continued efforts to improve
218 vaccine uptake are needed.

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234 **Author Contributions:** Dr Daly had full access to the study data and takes responsibility for
235 the integrity of the data and accuracy of the data analysis.

236 *Concept and design:* All authors.

237 *Acquisition, analysis, or interpretation of data:* All authors.

238 *Drafting of the manuscript:* All authors.

239 *Critical revision of the manuscript for important intellectual content:* All authors.

240 *Statistical analysis:* Daly.

241

242 **Role of the funding source:** There was no funding source for this study.

243

244 **Declaration of interests:** All authors report no conflicts of interest. ER has previously
245 received funding from the American Beverage Association and Unilever for projects
246 unrelated to the present research.

247

248 **Acknowledgements:** The project described in this paper relies on data from survey(s)
249 administered by the Understanding America Study, which is maintained by the Center for
250 Economic and Social Research (CESR) at the University of Southern California. The content
251 of this paper is solely the responsibility of the authors and does not necessarily represent the
252 official views of USC or UAS. The collection of the UAS COVID-19 tracking data is
253 supported in part by the Bill & Melinda Gates Foundation and by grant U01AG054580 from
254 the National Institute on Aging. However, these organizations bear no responsibility for the
255 analysis or interpretation of the data. ER's time was part-funded by the European Research
256 Council and their support is gratefully acknowledged.

257 **References**

- 258 1. World Health Organization (WHO). *WHO COVID-19 Weekly Epidemiological Update*.
259 2020: Available at: [https://www.who.int/publications/m/item/weekly-epidemiological-](https://www.who.int/publications/m/item/weekly-epidemiological-update---2-march-2021)
260 [update---2-march-2021](https://www.who.int/publications/m/item/weekly-epidemiological-update---2-march-2021)
- 261 2. Daly M, Sutin AR, Robinson E. Longitudinal changes in mental health and the COVID-19
262 pandemic: Evidence from the UK Household Longitudinal Study. *Psychol Med*. 2020.
263 doi:10.1017/S0033291720004432
- 264 3. Fernandes N. Economic effects of coronavirus outbreak (COVID-19) on the world
265 economy. *IESE Business School Working Paper No. WP-1240-E*. 2020. Available at
266 SSRN: <https://ssrn.com/abstract=3557504> or <http://dx.doi.org/10.2139/ssrn.3557504>
- 267 4. Bartsch SM, O'Shea KJ, Ferguson MC, et al. Vaccine efficacy needed for a COVID-19
268 coronavirus vaccine to prevent or stop an epidemic as the sole intervention. *Am J Prev*
269 *Med*. 2020;59(4):493-503.
- 270 5. Robinson E, Jones A, Daly M. International estimates of intended uptake and refusal of
271 COVID-19 vaccines: A rapid systematic review and meta-analysis of large nationally
272 representative samples. *Vaccine*. 2021. doi.org/10.1016/j.vaccine.2021.02.005
- 273 6. Lin C, Tu P, Beitsch LM. Confidence and receptivity for COVID-19 vaccines: a rapid
274 systematic review. *Vaccines*. 2021. doi.org/10.3390/vaccines9010016
- 275 7. Daly M, Robinson E. Willingness to vaccinate against COVID-19 in the US:
276 representative longitudinal evidence from April to October 2020. *Am J Prev Med*. 2021.
277 doi.org/10.1016/j.amepre.2021.01.008
- 278 8. Pfizer Inc. Pfizer and Biontech conclude Phase 3 study of COVID-19 vaccine candidate,
279 meeting all primary efficacy endpoints. November 18, 2020. Accessed on 3 March, 2021,
280 [https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-](https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-conclude-phase-3-study-covid-19-vaccine)
281 [conclude-phase-3-study-covid-19-vaccine](https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-conclude-phase-3-study-covid-19-vaccine)

- 282 9. U.S. Food and Drug Administration. FDA takes additional action in fight against COVID-
283 19 by issuing Emergency Use Authorization for second COVID-19 vaccine. December 18,
284 2020. Accessed on 3 March, 2021, [https://www.fda.gov/news-events/press-](https://www.fda.gov/news-events/press-announcements/fda-takes-additional-action-fight-against-covid-19-issuing-emergency-use-authorization-second-covid)
285 [announcements/fda-takes-additional-action-fight-against-covid-19-issuing-emergency-](https://www.fda.gov/news-events/press-announcements/fda-takes-additional-action-fight-against-covid-19-issuing-emergency-use-authorization-second-covid)
286 [use-authorization-second-covid](https://www.fda.gov/news-events/press-announcements/fda-takes-additional-action-fight-against-covid-19-issuing-emergency-use-authorization-second-covid)
- 287 10. U.S. Food and Drug Administration. FDA issues Emergency Use Authorization for third
288 COVID-19 vaccine. February 27, 2021. Accessed on 3 March, 2021,
289 [https://www.fda.gov/news-events/press-announcements/fda-issues-emergency-use-](https://www.fda.gov/news-events/press-announcements/fda-issues-emergency-use-authorization-third-covid-19-vaccine)
290 [authorization-third-covid-19-vaccine](https://www.fda.gov/news-events/press-announcements/fda-issues-emergency-use-authorization-third-covid-19-vaccine)
- 291 11. Our World in Data. Coronavirus (COVID-19) vaccinations. 2021. Accessed on 3 March
292 2021, <https://ourworldindata.org/covid-vaccinations>
- 293 12. Razai MS, Osama T, McKechnie DG, et al. Covid-19 vaccine hesitancy among ethnic
294 minority groups. *BMJ*. 2021;372:n513. doi.org/10.1136/bmj.n513
- 295 13. Reiter PL, Pennell ML, Katz ML. Acceptability of a COVID-19 vaccine among adults in
296 the United States: How many people would get vaccinated? *Vaccine*. 2020;38(42):6500-
297 6507.
- 298 14. Alattar L, Messel M, Rogofsky D. An introduction to the Understanding America Study
299 internet panel. *Soc Sec Bull*. 2018;78(2):13-28.
300 <https://www.ssa.gov/policy/docs/ssb/v78n2/v78n2p13.html>.
- 301 15. Kapteyn A, Angrisani M, Bennett D, et al. Tracking the effect of the COVID-19
302 pandemic on the lives of American households. *Surv Res Methods*. 2020;14(2):179-86.
303 doi.org/10.18148/srm/2020.v14i2.7737
- 304 16. Angrisani M, Kapteyn A, Meijer E et al. Sampling and weighting the Understanding
305 America Study. *WP No. 2019-004*. 2019. University of Southern California, Center for
306 Economic and Social Research. doi.org/10.2139/ssrn.3502405

- 307 17. Nguyen KH, Srivastav A, Razzaghi H, et al. COVID-19 vaccination intent, perceptions,
308 and reasons for not vaccinating among groups prioritized for early vaccination - United
309 States, September and December 2020. *MMWR Morb Mortal Wkly Rep* 2021;70:217-
310 222. doi: <http://dx.doi.org/10.15585/mmwr.mm7006e3>
- 311 18. Gold JA, Rossen LM, Ahmad FB, et al. Race, ethnicity, and age trends in persons who
312 died from COVID-19—United States, May–August 2020. *MMWR Morb Mortal Wkly*
313 *Rep.* 2020;69:1517-1521. doi.org/10.15585/mmwr.mm6942e1
- 314 19. Laine C, Cotton D, Moyer DV. COVID-19 vaccine: promoting vaccine acceptance. *Ann*
315 *Intern Med.* 2021;174(2):252-253.
- 316 20. Romer D, Jamieson KH. Conspiracy theories as barriers to controlling the spread of
317 COVID-19 in the US. *Soc Sci Med.* 2020;263:113356. doi.org/10.1016/
318 j.socscimed.2020.11335
- 319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337

338 Table 1.

339 Characteristics of participants in the Understanding American Study (UAS; N = 7,840;

340 Observations = 120,903).

Characteristic	Mean (SD) or %
Age, years	48.8 (16.6)
Age group (%)	
18-39	37.4
40-59	32.3
60+	30.3
Sex (%)	
Male	48.5
Female	51.5
Race/ethnicity (%)	
White	66.0
Hispanic	16.2
Black	11.9
Other race/ ethnicity	6.0
College degree (%)	
No	64.8
Yes	35.2
Household income level (%)	
< \$50,000	44.7
≥ \$50,000	55.3
Chronic condition ^a (%)	
No	66.1
Yes	33.9

341 Weighted estimates are presented.

342 ^a Diagnosed with any of the following: diabetes, cancer, heart disease, kidney disease, asthma,
343 chronic lung disease, an autoimmune disease.

344

345

346

347

348

349 Table 2.
 350 Vaccination intentions in the Understanding America Study (UAS) in April and October
 351 2020 and in February 2021 in the overall sample and demographic subgroups.

Survey month	Willing to accept vaccine			Unwilling to accept vaccine			Undecided		
	Apr 20 ^a	Oct 20 ^a	Feb 21 ^a	Apr 20 ^a	Oct 20 ^a	Feb 21 ^a	Apr 20 ^a	Oct 20 ^a	Feb 21 ^a
	%	%	%	%	%	%	%	%	%
Overall sample	73.8	52.8	60.9	16.0	32.4	29.1	10.2	14.8	10.0
Age group									
18-39	69.6	48.2	54.0	18.9	36.0	35.3	11.5	15.8	10.7
40-59	72.0	48.3	58.3	17.1	35.5	30.0	10.9	16.2	11.7
60+	81.0	63.2	72.0	11.1	24.8	20.8	8.0	12.1	7.2
Sex									
Male	79.3	59.2	65.6	13.6	28.5	26.5	7.2	12.3	7.9
Female	68.6	46.7	56.4	18.3	36.1	31.6	13.1	17.2	12.0
Race/ethnicity									
White	77.3	56.4	62.0	14.0	30.2	29.8	8.7	13.5	8.2
Hispanic	72.8	46.9	59.9	17.2	37.7	29.5	10.1	15.3	10.6
Black	48.9	31.9	47.1	29.1	44.2	32.6	22.0	24.0	20.3
Other race/ ethnicity	87.6	69.6	78.9	8.7	20.1	14.1	3.7	10.3	7.1
College degree									
No	68.1	44.4	52.9	19.1	36.9	34.1	12.8	18.7	13.0
Yes	84.8	67.9	75.6	10.0	24.3	20.1	5.3	7.8	4.4
Household income level									
< \$50,000	66.7	43.8	51.7	18.2	36.5	32.3	15.1	19.7	16.0
≥ \$50,000	79.5	60.0	68.3	14.2	29.2	26.6	6.3	10.8	5.1
Chronic condition									
No	71.3	51.3	54.1	18.3	34.1	34.7	10.4	14.6	11.2
Yes	78.6	55.6	65.5	11.5	29.3	24.9	9.9	15.2	9.6

352 Note: Weighted willingness to vaccinate estimates are presented.

353 ^aSurvey dates examined were Apr = April 1-14, 2020, Oct = September 30 – October 13 2020,
 354 and Feb = January 20 - February 15, 2021.

355 Table 3.

356 Regression estimates of percentage point changes in willingness to vaccinate between April and October 2020 and between October 2020 and

357 February 2021 in the Understanding America Study (UAS).

	Changes in willingness to vaccinate between April and October 2020 ^a			Changes in willingness to vaccinate between October 2020 and February 2021 ^b		
	Δ Willing to accept vaccine	Δ Unwilling to accept vaccine	Δ Undecided	Δ Willing to accept vaccine	Δ Unwilling to accept vaccine	Δ Undecided
	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)
Overall sample	-21.3*** (-23.3, -19.4)	16.6*** (14.8, 18.4)	4.7*** (3.1, 6.3)	8.1*** (6.3, 9.9)	-3.2*** (-5.0, -1.5)	-4.9*** (-6.2, -3.5)
Age 18-39	-22.0*** (-25.5, -18.4)	17.4*** (14.1, 20.7)	4.6** (1.6, 7.5)	5.2** (1.8, 8.5)	-0.3 (-3.6, 2.9)	-4.8*** (-7.4, -2.2)
Age 40-59	-23.9*** (-27.2, -20.5)	18.5*** (15.4, 21.7)	5.4*** (2.5, 8.2)	10.5*** (7.5, 13.4)	-5.7*** (-8.5, -2.9)	-4.7*** (-7.1, -2.4)
Age 60+	-18.1*** (-21.2, -15.1)	13.8*** (11.0, 16.6)	4.3*** (1.9, 6.7)	9.2*** (6.3, 12.1)	-4.2** (-7.0, -1.4)	-5.0*** (-7.1, -2.9)
Male	-20.3*** (-23.1, -17.6)	15.1*** (12.5, 17.7)	5.2*** (3.1, 7.4)	6.5*** (3.8, 9.1)	-2.0 (-4.4, 0.5)	-4.5*** (-6.4, 2.6)
Female	-22.3*** (-25.0, -19.6)	18.1*** (15.5, 20.6)	4.2*** (1.8, 6.6)	9.7*** (7.2, 12.1)	-4.4*** (-6.9, -2.0)	-5.2*** (-7.2, -3.2)
White	-21.4***	16.4***	4.9***	5.5***	-0.3	-5.2***

	(-23.5, -19.3)	(14.5, 18.4)	(3.3, 6.6)	(3.6, 7.5)	(-2.1, 1.5)	(-6.6, -3.8)
Hispanic	-25.2***	20.2***	5.1	12.1***	-7.5*	-4.5*
	(-31.5, -18.9)	(14.3, 26.0)	(-0.2, 10.3)	(6.2, 17.9)	(-13.3, -1.8)	(-8.8, -0.3)
Black	-17.3***	15.1***	2.2	15.6***	-11.6***	-4.0
	(-23.8, -10.7)	(8.6, 21.5)	(-4.3, 8.7)	(9.6, 21.7)	(-17.6, -5.6)	(-9.7, 1.7)
Other race/ethnicity	-18.5***	11.7***	6.8*	9.6***	-6.2	-3.4
	(-25.5, -11.6)	(5.7, 17.7)	(1.6, 12.0)	(2.4, 16.8)	(-12.9, 0.5)	(-8.8, 2.0)
No college degree	-23.7***	17.8***	5.9***	8.3***	-2.6*	-5.7***
	(-26.3, -21.1)	(15.4, 20.3)	(3.7, 8.1)	(5.9, 10.7)	(-4.9, -0.3)	(-7.6, -3.7)
College degree	-16.8***	14.4***	2.5*	7.7***	-4.3**	-3.4***
	(-19.5, -14.2)	(11.9, 16.8)	(0.5, 4.4)	(5.1, 10.2)	(-6.7, -1.7)	(-5.0, -1.8)
Income < \$50,000	-23.1***	18.4***	4.8**	8.0***	-4.1**	-3.9**
	(-26.3, -19.9)	(15.3, 21.4)	(2.0, 7.6)	(5.1, 10.9)	(-7.0, -1.3)	(-6.3, -1.4)
Income ≥ \$50,000	-19.9***	15.2***	4.7***	8.1***	-2.5*	-5.6***
	(-22.3, -17.5)	(13.0, 17.4)	(2.8, 6.5)	(5.8, 10.4)	(-4.8, -0.3)	(-7.2, -4.1)
No chronic condition	-20.3***	16.0***	4.3***	7.1***	-2.6*	-4.4***
	(-22.7, -17.8)	(13.7, 18.2)	(2.3, 6.3)	(4.8, 9.3)	(-4.8, -0.5)	(-6.1, -2.7)
Chronic condition present	-23.4***	17.9***	5.5***	10.0**	-4.4**	-5.6***
	(-26.5, -20.3)	(15.0, 20.8)	(2.9, 8.2)	(7.0, 13.0)	(-7.3, -1.4)	(-7.9, -3.4)

358 Note: Estimates are from marginal effects calculated after multinomial logistic regression and are adjusted for differences in covariates between waves.

359 ^a Changes in willingness to vaccinate between April 1-14 and September 30 - October 13 2020 survey waves are estimated.

360 ^b Changes in willingness to vaccinate between September 30 - October 13 2020 and January 20 - February 15 2021 survey waves are estimated.

361 * $p < .05$. ** $p < .01$. *** $p < .001$.

Figure 1.

Changes in vaccination intentions across 20 waves of the Understanding America Study conducted between April 1 2020 and February 15 2021. Graph is based on an analysis of 120,903 observations on 7,840 participants and estimates adjust for differences in demographic characteristics between survey waves. 95% confidence intervals are presented.




Table S1. Number of participants and response rate among participants in the current study by survey wave from April 1 2020 to February 15 2021 (N = 7,840, Obs. = 120,903).

Survey period ^a	N ^b	Response rate (%) ^c
All time points	7,840	–
April 1 – 14	5,371	68.5%
April 15 – 28	6,175	78.8%
April 29 – May 12	6,309	80.5%
May 13 – 26	6,260	79.8%
May 27 – June 9	6,274	80.0%
June 24 – July 7	5,955	76.0%
July 22 – August 4	6,243	79.6%
August 5 – 18	6,102	77.8%
August 19 – September 1	6,120	78.1%
September 2 – 15	6,156	78.5%
September 16 – 29	5,982	76.3%
September 30 – October 13	5,963	76.1%
October 14 – 27	6,051	77.2%
October 28 – November 10	6,129	78.2%
November 11 – 24	5,943	75.8%
November 25 – December 8	5,912	75.4%
December 9 – 22	5,917	75.5%
December 23 – January 5	5,919	75.5%
January 6 – January 19	6,041	77.1%
January 20 – February 15	6,081	77.6%

^a Responses were permitted for an additional two weeks after the allotted two-week slot for each survey wave and a small portion of responses (maximum $\approx 10\%$) of responses were made during this period and are included in the sample for each wave.

^b Number of observations included in the current study for each survey wave.

^c Indicates the percentage of the total number of participants included in the current study (N = 7,840) who have completed a survey in this wave.